By: IPP Bureau
Last updated : November 06, 2024 1:51 pm
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended September 30, 2024.
Granules India has posted a 5 per cent decline in its net profit at Rs. 97.2 crore in Q2 FY25 as compared to Rs. 102.1 crore in Q2 FY24. The company had posted net profit of Rs. 134.6 crore in Q1 FY25.
Revenue from Operations in Q2 FY25 stood at Rs. 966.6 crore as compared to 1,189.5 crore in Q2 FY24, representing a decline of 19 per cent. In Q1 FY25, Revenue from Operations was Rs. 1,179.9 crore.
The company has voluntarily paused production in the Gagillapur plant in September 2024 to reassess the potential risk on account of the US FDA observations, if any. Subsequently in October, the production was resumed in a staggered manner.
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24.
Finished dosages (FD), Active Pharmaceuticals Ingredients (API) and Pharmaceutical Formulation Intermediates (PFI) contributed 77%, 15%, and 8% of revenue from operations respectively for Q2FY25.
Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “Q2 sales were impacted by a voluntary pause in manufacturing and distribution from our Gagillapur facility. We delivered strong margins, supported by profitable formulations sales and a favourable product mix. Our operations also generated a healthy cash from operations of Rs. 200.7 crore. ”